Conditions: Renal Failure
Keywords: renal failure cardiopulmonary bypass
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 37
Healthy volunteers: no

Brief summary:
This project evaluates whether nesiritide, human recombinant brain natriuretic peptide, confers renal protection during cardiovascular surgery by attenuating the inflammatory response.

Detailed description:
This will be a randomized, prospective blinded pilot study comparing nesiritide to placebo in patients undergoing aortic arch, ascending aorta, aortic valve or mitral valve surgery with baseline GFR 30-90ml/min. Patients were randomized to either placebo or nesiritide (administered prophylactically starting in the operating room prior to incision at 0.01 mcg/kg /minute with no bolus and continued for 48 hours).

Arms:
arm 1: infuses at 0.01 MCG (micrograms)/KG (kilograms)/min (minute) for 48 hours arm 2: infuses at 0.01MCG/KG/min for 48 hours

Interventions: intervention 1: Nesiritide intervention 2: Placebo
Intervention descriptions: intervention 1: infuses at 0.01MCG/KG/min for 48 hours intervention 2: infuses at 0.01MCG/KG/min for 48 hours

Protocol document: